SERUM DIAGNOSIS OF MALIGNANT POTENTIAL OF ESOPHAGEAL CANCER

食管癌恶性潜能的血清诊断

• 批准号: 12671200
• 负责人: SHIMADA Hideaki
• 金额: $ 2.11万
• 依托单位: CHIBA UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2000
• 资助国家: 日本
• 起止时间: 2000 至 2002
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-12671200/
• 关键词: Esophageal Cancer; Serum Marker; Serum p53 antibody; VEGF; PDECGF; Midkine; ICTP; SCC-Ag; 腫瘍マーカー; p53抗体; VEGF; PyNPase; FasL; IAP; 血液パネル検査; 悪性度診断

In esophageal cancer patients, genetic analysis of cancer cells has been reported as an important tool to evaluate malignant potential of cancer cells. However, since protein analyzes reqiure tumor specimen and complicated techniques, a simpler and less invasive method for evaluating gene expression level is necessary for clinical application. Recently, gene & protein expression level in patients with various cancer has been made possible by measuring serum concentration with enzyme-linked immunosorbent assay (ELISA) have been reported to be raised in various cancer patients and was the prognostic factor closely associated with advanced tumor stage. We, therefore, analyzed serum markers in 340 patients with primary and recurrent esophageal cancer prior to treatment to determine the clinicopathological significance of serum markers. We found that most of the patients had high serum levels and, moreover, that high serum level was associated with advanced tumor stage treatment response and patietns' survival.

在食道癌患者中，癌细胞的基因分析已被报道为评估癌细胞恶性潜能的重要工具。然而，由于蛋白质分析需要肿瘤标本和复杂的技术，因此一种简单、创伤较小的评估基因表达水平的方法在临床上是必要的。近年来，通过酶联免疫吸附试验(EL ISA)检测血清浓度，使多种癌症患者的基因和蛋白表达水平成为可能，并被报道在多种癌症患者中升高，是与晚期肿瘤分期密切相关的预后因素。因此，我们分析了340例原发和复发食道癌患者治疗前的血清标志物，以确定血清标志物的临床病理意义。我们发现，大多数患者的血清水平都很高，而且，高水平的血清水平与晚期肿瘤的治疗反应和患者的生存有关。

项目成果

Akihiko Takeda: "Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients : correlation with clinicopathological factors and tumor markers."Oncol Report. 7. 333-338 (2000)

Akihiko Takeda：“结直肠癌患者血清血管内皮生长因子的临床意义：与临床病理因素和肿瘤标志物的相关性。”Oncol Report。

Shimada H, Nabeya Y, Okazumi S Matsubara H, Funami Y, Shiraton T, Hayashi H, Takeda A, Ochiai T: "Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma"Surgery. 132(1). 41-47 (2002)

Shimada H、Nabeya Y、Okazumi S Matsubara H、Funami Y、Shiraton T、Hayashi H、Takeda A、Ochiai T：“食管鳞状细胞癌患者血清 p53 抗体的预后意义”手术。

Akihiko Takeda, et al.: "Serum p53 antibody as a useful marker for monitaring of treatment of superficical colorectal adenocarcinoma after endoscopic resection"Int J. Clin Oncol. 6. 45-49 (2001)

Akihiko Takeda 等人：“血清 p53 抗体作为监测内窥镜切除术后浅表结直肠腺癌治疗的有用标志物”Int J. Clin Oncol。

Nabeya Y, Shimada H, Okazumi S, Matsubara H, Gunji Y, Suzuki T, Ochiai T: "Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma"Cancer. 94(4). 940-949 (20

Nabeya Y、Shimada H、Okazumi S、Matsubara H、Gunji Y、Suzuki T、Ochiai T：“I 型胶原蛋白的血清交联羧基末端肽 (ICTP) 作为食管鳞状细胞癌患者的预后肿瘤标志物”癌症。

Takeda A et al.: "Monitoring of p53 autoamtibodies after resection of colorectal cancer : Relationship to operative curability"Eur.J.Surg. 167(1). 50-53 (2001)

Takeda A 等人：“结直肠癌切除术后 p53 自身抗体的监测：与手术治愈率的关系”Eur.J.Surg。